Clinical Trials Logo
  1. Home
  2. Gastrointestinal Stromal Tumor
  3. NCT02508532

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Gastrointestinal Stromal Tumors (GIST) Clinical Trial

Official title:
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Clinical Trial Summary

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02508532
Study type Interventional
Source Blueprint Medicines Corporation
Contact
Status Completed
Phase Phase 1
Start date August 2015
Completion date June 3, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT00633295 - Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor Phase 2
Terminated NCT05160168 - A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Phase 1/Phase 2